Does Rallies show Form 4 insider transactions for MGTX?

Yes. Rallies tracks MGTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MGTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MGTX. It does not provide personalized investment advice.

MGTX (MeiraGTx Holdings plc Ordinary Shares) Stock Analysis - Insider Trades

MeiraGTx Holdings plc Ordinary Shares (MGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, MGTX trades at $9.58 with a market cap of $870.53M and a P/E ratio of -6.41. MGTX moved +4.71% today. Year to date, MGTX is +26.89%; over the trailing twelve months it is +74.18%. Its 52-week range spans $3.97 to $11.85. Analyst consensus is strong buy with an average price target of $24.00. Rallies surfaces MGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MGTX stock inside the company?

Recent MGTX insider activity includes Forbes Alexandria sold 62.00K, Giroux Richard sold 56.00K, Naylor Stuart sold 27.66K, Forbes Alexandria sold 62.00K, and Giroux Richard sold 24.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MGTX Key Metrics

Key financial metrics for MGTX
Metric	Value
Price	$9.58
Market Cap	$870.53M
P/E Ratio	-6.41
EPS	$-1.48
Dividend Yield	0.00%
52-Week High	$11.85
52-Week Low	$3.97
Volume	0
Avg Volume	0
Revenue (TTM)	$79.76M
Net Income	$-120.53M
Gross Margin	0.00%

Recent MGTX Insider Trades

Forbes Alexandria sold 62.00K (~$568.54K) on May 19, 2026.
Giroux Richard sold 56.00K (~$572.32K) on Apr 21, 2026.
Naylor Stuart sold 27.66K (~$258.91K) on Apr 7, 2026.
Forbes Alexandria sold 62.00K (~$459.42K) on Mar 24, 2026.
Giroux Richard sold 24.00K (~$212.88K) on Oct 21, 2025.

Latest MGTX News

MeiraGTx Reports FDA Breakthrough, Raises $100M, Acquires Bota-vec for $25M — May 14, 2026
MeiraGTx Prices $100M Offering at $9 to Fund Gene Therapy Launches — Apr 16, 2026
MeiraGTx Shows 3-Year Saliva Flow Gains and Durable Xerostomia Relief — Apr 16, 2026
Breakthrough Status for Xerostomia Therapy; $200M AI JV and Lilly Ocular Deal — Mar 26, 2026

MGTX Analyst Consensus

6 analysts cover MGTX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.00.

Common questions about MGTX

Who is trading MGTX stock inside the company?: Recent MGTX insider activity includes Forbes Alexandria sold 62.00K, Giroux Richard sold 56.00K, Naylor Stuart sold 27.66K, Forbes Alexandria sold 62.00K, and Giroux Richard sold 24.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MGTX?: Yes. Rallies tracks MGTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MGTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MGTX. It does not provide personalized investment advice.